ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Clinical Trial ID NCT01598129

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Oncolytic viruses for cancer therapy.	Oncoimmunology	2013	1.36
2	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2013	1.31
3	Trial Watch:: Oncolytic viruses for cancer therapy.	Oncoimmunology	2014	1.22
4	Glioma virus therapies between bench and bedside.	Neuro Oncol	2014	0.95
5	Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.	Oncoimmunology	2015	0.91
6	Recent advances in oncolytic adenovirus therapies for cancer.	Curr Opin Virol	2016	0.87
7	Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.	Mol Ther Methods Clin Dev	2016	0.86
8	Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization.	Oncoimmunology	2014	0.85
9	Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.	J Immunother Cancer	2016	0.85
10	EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.	Drugs Future	2016	0.84
11	Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.	Hum Gene Ther	2015	0.83
12	Trial Watch-Oncolytic viruses and cancer therapy.	Oncoimmunology	2015	0.83